Key terms
About AVRO
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AVRO news
Mar 16
2:01am ET
AVROBIO’s Strategic Ambiguity: A Commitment to Analysis with Uncertain Outcomes for Shareholders
Jan 31
5:50am ET
Avrobio Buy Rating: Undervalued Merger Potential with Tectonic and Promising Fc-relaxin Asset for G2PH
Jan 30
8:07am ET
Avrobio, Tectonic Therapeutic to combine in an all-stock transaction
No recent press releases are available for AVRO
AVRO Financials
Key terms
Ad Feedback
AVRO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AVRO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
